# A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults

> **NCT04268420** · PHASE1 · UNKNOWN · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 46 (estimated)

## Conditions studied

- Vaccine Reaction

## Interventions

- **DRUG:** FMP013
- **DRUG:** ALFQ

## Key facts

- **NCT ID:** NCT04268420
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-20
- **Primary completion:** 2023-07
- **Final completion:** 2023-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268420, "A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04268420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*